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Abstract
Background: Desmoid tumors are intermediary malignant, fibrous lesions occurring in various soft tissues. Surgical
treatment is relentlessly challenging because of the propensity for local aggressive behavior and high risk of
recurrence. Consequently, a wide range of oncological drugs and radiation therapy are being used; however,
outcomes are unpredictable. We investigated whether local treatment with an oncolytic peptide could be
beneficial in a patient with an unresectable desmoid tumor.
Case presentation: In a young 29-year-old Caucasian woman who was diagnosed with a retromammary desmoid
tumor infiltrating deeply into the anterior thoracic wall, surgery was considered excessively mutilating, and
observation was recommended. The lesion progressed, however, and caused debilitating pain, despite nonsteroidal
anti-inflammatory medication. Subcutaneous injections of human interferon-α (Multiferon®) resulted in reduced
growth kinetics but had to be terminated because of development of symptomatic pneumonitis. Frequently used
oncological treatment was withheld because of the toxicity profile, and the patient was instead included in a phase
I study investigating transdermal intratumoral injection of LTX-315, an oncolytic peptide that induces anticancer
immune responses (ClinicalTrials.gov, NCT01986426). A marked increase of CD8+ tumor-infiltrating T cells in the
lesion was complemented by upregulation of immune gene signature (including effector T-cell, T-helper type 1 cell,
chemokine, and cytokine genes). These changes were followed by gradual symptom relief and long-term disease
stabilization, indicating clinical benefit. LTX-315 was well tolerated until termination in week 16 after a serious
allergic reaction.
Conclusions: Our patient was treated with repeated intratumoral injections of LTX-315, resulting in tumor
regression accompanied by upregulation of immune genes and T-cell infiltration. Local application of
immunotherapy, minimizing systemic side effects, represents a novel treatment modality in desmoid tumors that
should be tested in further clinical trials.
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Background
Desmoid tumors (DTs) or aggressive fibromatoses are
rare, with a yearly incidence of 2–5 per 1 million popu-
lation. Not apt to metastasize, they represent locally in-
filtrating soft tissue tumors that may occur anywhere in
the body [1]. A seemingly multifactorial pathogenesis,
including physical trauma, endocrine factors, and genetic
aspects, induces a proliferation of fibroblasts, resulting
in extremely hard, fibrotic lesions [2], approximately
90% of which comprise a somatic mutation of β-catenin
(CTNNB1) [3]. The peak incidence is in the second to
fourth decades of life, and a preponderance of the pa-
tients are female; otherwise, the sex incidence is equal in
pediatric and older patients. The clinical development
varies greatly from incidental findings of indolent course
to progressive and mutilating disease imposing pain,
major functional deficits, and even death in the case of
intra-abdominal location. Symptomatic lesions call for
action; however, treatment is challenging and often re-
quires a trial-and-error approach [4–6]. Owing to the
confined nature of the disease, it seems rational to favor
local treatment. Surgery often necessitates extensive resec-
tions and is associated with a high risk of local recurrence;
hence, surgical excision is no longer considered a mainstay
strategy [4, 5]. Radiotherapy entails a risk of severe late
morbidity and secondary cancer. Recommended medica-
tions range from nonsteroidal anti-inflammatory drugs
(NSAIDs) and endocrine treatment to kinase inhibitors
and toxic chemotherapy [7–11]. Immune therapy with
recombinant interferon-α (IFN-α) or a human leukocyte
derived mixture of naturally occurring IFN-α subtypes
(Multiferon®) has been described as effective in selected
cases [12, 13].
Relative contraindications to frequently used treatment
options in a case of a young woman with a retromam-
mary DT motivated the investigation of intratumoral in-
jection of an oncolytic peptide within an ongoing phase
I study in solid tumors. Long-term clinical benefit was
achieved.
Case presentation
A young Caucasian woman (aged 29 years) was diag-
nosed in January 2013 with a DT (5 cm in longest diam-
eter) infiltrating deeply into the left thoracic wall and
involving multiple layers of soft tissue. Her only symp-
tom was a palpable lesion; she had no pain. Surgery aim-
ing for a wide safety margin would have required a
massive resection and was considered contraindicated.
During surveillance, the lesion gradually enlarged to ap-
proximately 8 cm, accompanied by increasing aching
and tenderness. In addition, the patient experienced at-
tacks of intense neuropathic pain causing frequent noc-
turnal awakenings, as well as restricted function of her
left arm. Progressing tumor and debilitating symptoms
compelled medical treatment. NSAIDs partially reduced
pain but not tumor growth. Endocrine therapy with tam-
oxifen was discarded because the patient wanted a sec-
ond child, and teratogenic effects have been reported
and may persist as a risk many months after cessation of
tamoxifen [14]. Instead, on the basis of Scandinavian ex-
perience, the patient received human IFN-α (Multiferon®)
at a dose of 3 million IU daily administered subcutane-
ously in the period from May through August 2014 [12,
13]. Radiological evaluation demonstrated reduced growth
kinetics and disease stabilization. However, the patient de-
veloped pneumonitis, and Multiferon® had to be stopped
prematurely. Her pain did not diminish, but it was par-
tially alleviated by ibumetin and later celecoxib in combin-
ation with paracetamol. Despite receiving pain relievers,
she woke up approximately ten times every night and
developed symptoms of sleep deprivation. Her young age
and the retromammary localization of the tumor informed
her reluctance to undergo radiotherapy, owing to a
long-term risk of secondary breast cancer. Tyrosine kinase
inhibitors have demonstrated promising progression-free
survival, but only rarely has a partial regression pertinent
to mitigating symptoms been achieved. Moreover, stable
disease was already achieved with Multiferon®. Because
the patient responded to immunotherapy with IFNs, we
postulated that her tumor also might respond to intratu-
moral immunotherapy. She was therefore recruited to
undergo local injection of an oncolytic peptide (LTX-315;
Lytix Biopharma, Oslo, Norway) in an ongoing phase I
study of solid tumors (ClinicalTrials.gov, NCT01986426)
[15, 16].
Investigations
Initially, the patient was examined at a breast diagnostic
center. Core biopsy revealed a fibrous lesion of
spindle-shaped cells in a fascicular pattern with uniform
nuclei. No epithelial components were evident. IHC
demonstrated strong positivity for vimentin in addition
to positivity for β-catenin and actin 1A4, slight positivity
for desmin, and focal positivity for actin HHF35. Weak
positivity for estrogen was spotted in single endothelial
cells, although not in spindle-shaped cells. Ki67 expres-
sion was < 5%. Altogether, the findings supported a diag-
nosis of extra-abdominal DT. Additional molecular
diagnostics detected a mutation in exon 3 of CTNNB1,
codon 45 (S45F).
Diagnostic magnetic resonance imaging (MRI) and
baseline MRI prior to LTX-315 demonstrated an irregu-
larly shaped soft tissue mass with a moderate contrast
uptake situated close to the axillary process and cranial
component of the left breast, infiltrating dorsolateral
parts of the pectoralis minor and major muscles, as well
as anterior parts of the serratus, latissimus dorsi, and
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intercostal muscles. In the superficial direction, the le-
sion infiltrated the subcutaneous fatty tissue.
Positron emission tomography/computed tomography
demonstrated only a minor fluorodeoxyglucose uptake
(maximum standardized uptake value, 3.2) in the lesion
and was considered unsuitable for evaluation. Baseline
Ultrasound (US) was used to guide LTX-315 injections
and for continuous evaluation during the study, in
addition to MRI. Baseline Ultrasound (US) revealed a
nonsymmetric and diffusely demarcated lesion. In line
with the phase I protocol, research core biopsies were
undertaken at baseline (week − 1), after induction (week
7), and at the end of treatment (week 18) (Fig. 1).
Tumor tissue was evaluated by H&E (Haemotoxylin
and Eosin) staining as well as staining of CD3+ and
CD8+ T cells in the pretreatment biopsy, following in-
duction, and at the end of treatment. Next-generation
sequencing of the β-T-cell receptor genes was applied in
order to detect clonal expansion of tumor-associated
peripheral blood mononuclear T cells in blood, including
clones that also were present in the tumor. Identification
of upregulated key immune genes involved in tumor re-
gression was carried out by hierarchical clustering of
Immunosign 21 immune gene signature (HalioDx, Rich-
mond, VA, USA) by means of a predefined set of genes,
including effector T-cell, T-helper type 1 (Th1) cell, che-
mokine, and cytokine genes.
Differential diagnosis
Upon referral to the hospital, the patient was informed
that a primary breast cancer was suspected. However, in
contrast to most breast carcinomas, the lesion was not
detected by mammography. Other clinical differential
diagnoses for DTs are a variety of fibromas, nodular fas-
ciitis, or soft tissue sarcoma. Histopathologically, the
most frequent misclassifications are Gardner fibroma,
scar tissue, superficial fibromatosis, nodular fasciitis,
myofibroma, collagenous fibroma, and low-grade fibro-
myxoid sarcoma [17].
Treatment
LTX-315 is an oncolytic peptide derived from lactoferrin,
a membrane host defense peptide. When injected into
malignant tumors, LTX-315 targets mitochondria and
prompts direct cell death by disintegrating cytoplasmic
organelles [18]. Release of tumor antigens, in turn, in-
duces specific systemic anti-tumor responses by en-
hanced T-cell clonality and an enhanced number of
tumor-infiltrating T cells, transforming non-T-cell in-
flamed cold tumors into T-cell-inflamed hot targets
(Fig. 2) [19]. This mechanism of action has been demon-
strated in the current phase I study, from which clinical
trial data are to be published.
LTX-315 (5mg; 20mg/ml) was injected under US guid-
ance into the tumor tissue and deposed immediately in-
side the pseudocapsule in a clockwise manner for the
following intervals: days 1 and 3 during the first week,
once weekly thereafter for a total of 6 weeks, followed by a
maintenance phase with one injection every second week
until maintenance week 9 (Fig. 1). Local pain during and
shortly after the injection varied from mild to severe; how-
ever, no pain medication was necessary, owing to only
short-term discomfort. Allergy-like reactions such as hot
flushes and mild edema of the face and arms were en-
countered after the first two injections but subsided until
the 11th dose, after which the patient reported hot flushes
and edema of her upper body, itching, nausea, hyperten-
sion, and tachycardia (all grade 1 adverse events according
to National Cancer Institute Common Terminology Cri-
teria for Adverse Events), in addition to grade 2 headache,
dizziness, and swelling of the throat. The subsequent dose
was therefore administered with premedication (antihista-
mines and dexamethasone) 12 hours and 1 hour prior to
study drug application. Despite allergy prophylaxis, fol-
lowing the 12th dose, a grade 3 anaphylactic reaction oc-
curred immediately after the injection, presenting with
symptoms similar to those described above except more
pronounced, including edema of the throat classified as
grade 3. The patient’s respiratory distress was quickly re-
lieved with subcutaneous administration of adrenaline
(0.3mg). All symptoms resolved nearly entirely within 30
minutes, and she was discharged from the Clinical Trial
Unit the same afternoon. Apart from moderate tiredness
for the next couple of days, she completely recovered.
Evidently, this anaphylactic episode led to termination of
the treatment.
Fig. 1 This diagram has been provided to the author by Lytix Biopharma and approved for use in this article by medical chief officer as well as
co-founder of Lytix Biopharma
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Outcome and follow-up
Following the anaphylactic reaction, supplementary tests
were performed to investigate the underlying immunological
mechanisms. The result of a skin prick test was negative,
whereas the result of a subsequent intradermal skin test was
considered positive. A transient rise in eosinophils shortly
after the reactions was measured. Results of a basophil acti-
vation test and histamine release test were both interpreted
as positive. Antibody investigation (manual enzyme-linked
immunosorbent assay) revealed specific immunoglobulin G
(IgG) antibodies against LTX-315, although no specific IgE
antibodies were found. Specific IgG antibodies may form
immune complexes with LTX-315, thereby activating com-
plement. Complement activation factors such as C3a and
C5a may directly activate basophils and mast cells, possibly
explaining the test results.
Radiologically, the pretreatment tumor size in May 2015
was 8.6 × 7.9 × 2.9 cm based on MRI, corresponding to 3.6
Fig. 2 LTX-315 mode of action
A B
C D
Fig. 3 Radiological evaluation. Magnetic resonance imaging (t1 weighted) demonstrating frontal (a, b) (yellow arrows indicating cranial tumour
border) and axial (c, d) (yellow arrows indicating medial tumour border) sections of pretreatment (a, c) and follow-up (b, d) examination 19
months after completion of intratumoural LTX-315 injections
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cm in thickness, 8.1 cm craniocaudally, and 9.1 cm antero-
posteriorly on a baseline US scan. By the time of the last in-
jection, the lesion had decreased to 7.0 × 7.0 × 2.5 cm based
on US. Similarly, the tumor had slightly decreased in size to
7.0 × 6.0 × 2.0 cm based on MRI, becoming clinically less
prominent 4months after the start of LTX-315 (Fig. 3). A
reduction of the greatest tumor diameter by 19% qualified
for stable disease according to RECIST 1.1 criteria (Re-
sponse Evaluation Criteria in Solid Tumours). No morpho-
logic changes were apparent on US scans during the study
period.
Histopathologically, abundant infiltration of CD3+ and
CD8+ T cells was demonstrated in the biopsies obtained
at week 7 and at the end of treatment (18 weeks from
start of LTX-315) compared with the pretreatment bi-
opsy done in May 2015 (Fig. 4). The number of CD3+ T
cells in two different biopsies increased by a factor of
16.7 from averages of 76.7 and 43.0 per mm2 of tumor
tissue at baseline to 817.1 and 1181.9 per mm2 of tumor
tissue at 7 weeks. Similarly, the subpopulation of CD8+
T cells in the two biopsies at baseline and postinduction
(week 7) increased approximately sevenfold from 74.2
and 32.1 to 329.4 and 422.8 cells per mm2 of tumor tis-
sue. Altogether, 52 T-cell clones among peripheral blood
mononuclear cells (PBMC) expanded significantly fol-
lowing drug exposure, 19 of which were present in the
tumor tissue in the post-treatment biopsy (Fig. 5). By
profiling a predefined set of effector T cell, Th1 cell, che-
mokine, and cytokine genes, a change from cold to hot
gene expression confirmed upregulation of immune
genes typically involved in tumor regression (Fig. 6).
Clinically, the patient’s complaints of short pulses of
stinging pain of neuropathic character changed to more
constant pain of lower intensity during the course of
LTX-315 therapy. Except for the treatment days, the pa-
tient was able to attend work during the study period. The
aching pain gradually decreased in amplitude over time,
and by March 2016, she reported that she had stopped
taking pain medication, hardly ever woke up during the
night, and was able to resume playing handball. Concur-
rent MRI revealed that the tumor was shrinking slowly
(6.5 × 6.1 × 1.9 cm), representing a tumor diameter reduc-
tion of 24% from baseline. The lesion has been stable
based on subsequent follow-up MRI scans more than 2.5
years after the completion of study treatment.
Discussion and conclusions
DTs are classified as intermediate malignant lesions be-
cause of their infiltrative behavior [1]. Surveillance is
recommended in asymptomatic cases because surgery
entails a high risk of local recurrence correlating with
the quality of the surgical margin [20]. Treatment is
challenging in cases of rapid progression, and the sever-
ity of the disease directs the treatment decision process
[4–6]. When prompt response is crucial because of com-
promised function of vital organs, chemotherapy in
oncological doses is typically the first choice [7]. Less
dramatic development may motivate low-dose chemo-
therapy, IFN-α, or, more recently, tyrosine kinase inhibi-
tors [8, 9]. Tamoxifen and NSAIDs (typically sulindac)
are attempted in more indolent cases [10, 11].
Histopathological examination of DTs reveals uniform,
spindle-shaped, small-nucleated cells within a collagen-
rich stroma and variable prominent vessels or occasionally
perivascular edema. Cellular atypia is absent [1]. Activat-
ing mutations of the CTNNB1 gene are detected in the
majority of sporadic DTs counteracting the normal
Fig. 4 Pre- and post-treatment biopsies. Haemotoxylin and Eosin staining and staining of CD3+ and CD8+ T cells in pretreatment biopsy (left
column), postinduction week 7 (middle column), and at the end of treatment 18 weeks later (right column)
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inhibitory effects of adenomatous polyposis coli (APC)
protein on the β-catenin complex, a downstream effector
of which the intricate function involves pleiotropy, inter-
action with transcription factors, cell growth, and homeo-
static processes [3]. β-Catenin plays a key role in the
Wnt-signaling cascade responsible for embryonal forma-
tion of tissue and organ development, as well as in cell
regulation and regeneration in adults.
DTs most frequently arise in the abdominal wall in
young/middle-aged women, in whom there is an associ-
ation with pregnancy. Other locations are deep-seated,
poorly circumscribed fibromatosis of the trunk wall, girdles,
and head and neck area. Individuals with familial adenoma-
tous polyposis (FAP) harbor an increased susceptibility to
develop mesenteric/intra-abdominal DTs because germline
inactivation of the APC tumor suppressor gene found in
patients with FAP interrupts APC/β-catenin binding,
resulting in inhibition of the Wnt pathway [21].
In young females, endocrine treatment with tamoxifen
is considered first choice by many [22]. When we in-
formed our patient about potential teratogenic side ef-
fects, she rejected this option. Anti-inflammatory drugs
are frequently administered, but with limited success in
most patients, as in our patient. Chemotherapy (acute
Fig. 5 T-cell analyses. a Graph showing the abundance of unique T-cell clones in blood (peripheral blood mononuclear cells) before treatment
compared with 7 weeks after initiation of LTX-315 treatment. T-cell clones that were not significantly changed in frequency are depicted in gray,
whereas those that were significantly expanding or contracting are depicted in red or blue, respectively. Dashed diagonal gray line defines
frequency equality, and dashed red line defines threshold for statistical comparison. b Trivariate analysis of T-cell clones in blood (similar analysis
to that in a) compared with the T-cell clones in the tumor after LTX-315 treatment. T-cell clones colored without transparency and with a black
peripheral line were also present in the tumor tissue
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and late toxicity concerns) and radiation (time-depen-
dent risk of developing secondary cancer) were consid-
ered last-resort alternatives. Because of the relatively
aggressive growth kinetics, we suggested human IFN-α,
referring to a retrospective Norwegian study (see details
below) [13]. Although side effects of IFNs may be dis-
tressing, they typically attenuate within a few weeks after
commencing treatment and dissipate within 2 weeks
after termination.
It is speculated whether DTs are offshoots of an
out-of-control repair process following tissue injury;
hence, an immunological mechanism may well play a
part in the pathophysiological process. This is sup-
ported by clinical effects of NSAIDs and IFN [12, 23,
24]. In the period 2008–2013, Poulsen et al. con-
ducted a study at the Norwegian Radium Hospital
using Multiferon®, a purified, multi-subtype IFN-α
product containing α1, α2, α8, α10, and α21, in pa-
tients with locally advanced DTs. Daily doses of 3
million International Units (IU) × 6 days/week were
injected subcutaneously. The outcomes in 18 treated
patients were partial response in 5, stable disease in
11, and progressive disease in 1, and 1 was not evalu-
ated [13]. Treatment time ranged from 8 to 38
Fig. 6 Gene expression profiles. LTX-315 induced upregulation of key genes involved in tumor regression and transformed the gene expression
from cold (blue) to hot (red). Hierarchical clustering of Immunosign 21 immune gene signature (HalioDx) profiling a predefined set of effector T-
cell, T-helper type 1 cell, chemokine, and cytokine genes
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months and resulted in symptom relief in the major-
ity of patients.
Our patient received Multiferon® in similar daily doses
for 4 months, resulting in disease stabilization. Side ef-
fects were flulike symptoms and malaise. With time,
however, she developed a dry cough and dyspnea. Com-
puted tomographic findings correlated with pneumon-
itis, a relatively rare but known severe side effect of IFN,
which had to be stopped.
Suggested immunological activity in the lesion moti-
vated further immunotherapy with local application to
reduce the risk of systemic side effects. Weighing the
risks of experimental treatment against chemotherapy or
radiotherapy harmfulness, building on a favorable tox-
icity profile of LTX-315 in animal models and early hu-
man testing, the patient was thoroughly informed about
and consented to participation in the phase I study of
transdermal injection of the oncolytic peptide LTX-315
in solid tumors. Intratumoral LTX-315 resulted in rever-
sal of tumor growth kinetics in parallel with gradual
symptom relief and a slight decline in tumor diameter.
Ongoing stable disease represents a successful long-term
outcome.
Safety aspects in 61 patients receiving LTX-315 at
doses of 2–7 mg/injection displayed 11 cases of grades
3–4 allergic reactions, the most serious (anaphylaxis) of
which occurred after > 10 weeks of treatment, indicating
development of specific antibodies over time with re-
peated drug exposure. This was taken into account in
the amended protocol, restricting treatment time to a
total of 3 weeks, compensated with multiple concurrent
injections in one or more lesions. Commonly recorded
adverse events were mild and transient hypotension,
flushing, skin rash, and pruritus in approximately 50%.
All allergy-like reactions typically subsided within ap-
proximately 30 minutes, with no late sequelae.
In summary, in cases of DTs interfering with daily
function, action is warranted in order to control the
disease. The therapeutic outcomes achieved with dif-
ferent drugs are unpredictable, although in general,
the more toxic the therapy chosen from the arma-
mentarium, the greater the anticipated effectiveness.
In our patient, we opted for an experimental drug in
a third-line setting (following NSAIDs and IFN-α).
Occurrence of a severe allergic reaction led to ter-
mination of the study drug. Altogether, a 16-week
period of LTX-315 therapy was followed by a gradual
change in pain. Despite increased local tenderness
during the treatment period, a long-term improve-
ment of distress complemented by a slow reduction
of tumor size suggested clinical benefit. A polyclonal
expansion of PBMC was accompanied by an almost
17-fold increase in CD3+ T lymphocytes infiltrating
the tumor tissue, transforming the immune gene
expression from cold to hot and confirming activity
of the drug. A slowly symptomatic recovery over sev-
eral months in respect to improved sleep and physical
functioning due to alleviated pain supports this con-
clusion. Further studies using local immunotherapy
with LTX-315 in patients with DTs seem justified.
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